Merck halts 1bn London HQ as pharma giant attacks UK support for life sciences
Merck cancelled its £1bn London HQ and halted UK discovery research, citing insufficient life sciences investment and restrictive NHS drug-pricing, cutting 125 jobs.
Wes Streeting's row with pharma firms grows as talks end on NHS drug pricing
Government and pharmaceutical companies remain deadlocked over VPAG NHS drug pricing, so the existing high clawback rate will continue, risking reduced UK medicine launches.